Press-release for stocks for 9 meters biopharma, inc.

Prices are updated after-hours

entities : 9 meters biopharma, inc. source : Www.biospace.com

save search

9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome
Published: 2023-05-30 (Crawled : 17:00) - biospace.com/
NMTR | $0.0722 -42.97% -67.9% 10M

Health Technology

| -90.98% | O: -13.75% H: 8.8% C: -4.38%
management change update biopharma

9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity
Published: 2023-04-05 (Crawled : 16:00) - biospace.com/
NMTR | $0.0722 -42.97% -67.9% 10M

Health Technology

| -94.61% | O: 0.75% H: 1.48% C: -2.22%
nm-136 fda obesity biopharma meeting

9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022
Published: 2023-03-28 (Crawled : 13:00) - biospace.com/
NMTR | $0.0722 -42.97% -67.9% 10M

Health Technology

| -94.61% | O: -2.24% H: 3.82% C: 3.05%
business year update biopharma financial results

9 Meters Biopharma Announces $5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
Published: 2023-03-14 (Crawled : 12:20) - biospace.com/
NMTR | $0.0722 -42.97% -67.9% 10M

Health Technology

| -95.43% | O: -10.13% H: 4.94% C: 2.11%
offering biopharma nasdaq direct

9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
Published: 2023-03-07 (Crawled : 14:00) - biospace.com/
NMTR | $0.0722 -42.97% -67.9% 10M

Health Technology

| -95.83% | O: -0.58% H: 0.0% C: -4.07%
biopharma conference

9 Meters Biopharma to Present at the 2023 BIO CEO & Investor Conference
Published: 2023-01-31 (Crawled : 13:20) - biospace.com/
NMTR | $0.0722 -42.97% -67.9% 10M

Health Technology

| -96.37% | O: 0.5% H: 4.5% C: 1.0%
biopharma ceo conference

Corium Pharma Solutions Appoints Mark Sirgo as Chief Executive Officer
Published: 2023-01-17 (Crawled : 14:00) - biospace.com/
GNTA | $3.67 1.1% 42K

n/a

| -43.72% | O: -0.62% H: 0.62% C: 0.62%
PG S | $162.25 0.46% 2.7M

Consumer Non-Durables

| 7.04% | O: -0.06% H: 0.89% C: -0.23%
COLL | $35.43 -1.42% 39K

Health Technology

| 25.1% | O: -1.01% H: 1.93% C: -0.18%
AGRX | $0.37 95K

Health Technology

| -97.45% | O: 2.93% H: 0.5% C: -3.79%
NMTR | $0.0722 -42.97% -67.9% 10M

Health Technology

| -96.9% | O: 0.43% H: 0.0% C: -5.56%
pharma solutions

9 Meters Biopharma Presents Preclinical Data on Glucose-Dependent Insulinotropic Polypeptide (GIP) Monoclonal Antibodies for Obesity at the American College of Gastroenterology 2022 Annual Scientific Meeting
Published: 2022-10-24 (Crawled : 13:20) - biospace.com/
NMTR | $0.0722 -42.97% -67.9% 10M

Health Technology

| -96.69% | O: 0.0% H: 5.21% C: 0.92%
obesity biopharma preclinical meeting

9 Meters Biopharma to Present at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
Published: 2022-10-18 (Crawled : 13:00) - biospace.com/
NMTR | $0.0722 -42.97% -67.9% 10M

Health Technology

| -97.97% | O: 3.09% H: 0.82% C: -23.16%
biopharma meeting

9 Meters Biopharma Provides Business Update and Reports Financial Results for Second Quarter 2022
Published: 2022-08-15 (Crawled : 12:00) - biospace.com/
NMTR | $0.0722 -42.97% -67.9% 10M

Health Technology

| -98.66% | O: 0.33% H: 7.41% C: 7.41%
biopharma update

9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome
Published: 2022-06-30 (Crawled : 12:20) - biospace.com/
NMTR | $0.0722 -42.97% -67.9% 10M

Health Technology

| -80.01% | O: -14.4% H: 7.09% C: -15.63%
biopharma phase 3

9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome
Published: 2022-06-30 (Crawled : 12:20) - biospace.com/
NMTR | $0.0722 -42.97% -67.9% 10M

Health Technology

| -80.01% | O: -14.4% H: 7.09% C: -15.63%
biopharma positive results phase 2

9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation
Published: 2022-06-21 (Crawled : 13:00) - biospace.com/
NMTR | $0.0722 -42.97% -67.9% 10M

Health Technology

| -86.88% | O: -53.55% H: 0.0% C: 0.0%
biopharma disease trial phase 3

9 Meters Biopharma to Participate in the 2022 BIO International Convention
Published: 2022-06-13 (Crawled : 22:00) - biospace.com/
NMTR | $0.0722 -42.97% -67.9% 10M

Health Technology

| -87.49% | O: -3.71% H: 13.39% C: 11.59%
biopharma international

9 Meters Biopharma to Exhibit at Digestive Disease Week 2022
Published: 2022-05-19 (Crawled : 13:00) - biospace.com/
NMTR | $0.0722 -42.97% -67.9% 10M

Health Technology